| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| B C Ho, D Miller, P Nopoulos, N C Andrease. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. The Journal of clinical psychiatry. vol 60. issue 10. 1999-11-10. PMID:10549681. |
risperidone and olanzapine have each been demonstrated to be efficacious and safe in the treatment of patients with chronic schizophrenia. |
1999-11-10 |
2023-08-12 |
Not clear |
| D A Wirshing, B D Marshall, M F Green, J Mintz, S R Marder, W C Wirshin. Risperidone in treatment-refractory schizophrenia. The American journal of psychiatry. vol 156. issue 9. 1999-09-27. PMID:10484947. |
risperidone in treatment-refractory schizophrenia. |
1999-09-27 |
2023-08-12 |
Not clear |
| D A Wirshing, B D Marshall, M F Green, J Mintz, S R Marder, W C Wirshin. Risperidone in treatment-refractory schizophrenia. The American journal of psychiatry. vol 156. issue 9. 1999-09-27. PMID:10484947. |
the purpose of this study was to evaluate the clinical safety and efficacy of risperidone compared to haloperidol in patients with treatment-refractory schizophrenia. |
1999-09-27 |
2023-08-12 |
Not clear |
| R S Kern, M F Green, B D Marshall, W C Wirshing, D Wirshing, S R McGurk, S R Marder, J Mint. Risperidone versus haloperidol on secondary memory: can newer medications aid learning? Schizophrenia bulletin. vol 25. issue 2. 1999-09-24. PMID:10416728. |
the present study compared the effects of risperidone and haloperidol on secondary memory in a group of treatment-resistant schizophrenia patients. |
1999-09-24 |
2023-08-12 |
Not clear |
| H Y Meltzer, S R McGur. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia bulletin. vol 25. issue 2. 1999-09-24. PMID:10416729. |
the effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. |
1999-09-24 |
2023-08-12 |
Not clear |
| H Y Meltzer, S R McGur. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia bulletin. vol 25. issue 2. 1999-09-24. PMID:10416729. |
we have identified all the studies of clozapine, olanzapine, and risperidone that provide data on their effects on cognition in schizophrenia. |
1999-09-24 |
2023-08-12 |
Not clear |
| N M Desai, Z Huq, S D Martin, G McDonal. Switching from depot antipsychotics to risperidone: results of a study of chronic schizophrenia. The Schizophrenia Treatment & Assessment Group. Advances in therapy. vol 16. issue 2. 1999-09-14. PMID:10539380. |
switching from depot antipsychotics to risperidone: results of a study of chronic schizophrenia. |
1999-09-14 |
2023-08-12 |
Not clear |
| N M Desai, Z Huq, S D Martin, G McDonal. Switching from depot antipsychotics to risperidone: results of a study of chronic schizophrenia. The Schizophrenia Treatment & Assessment Group. Advances in therapy. vol 16. issue 2. 1999-09-14. PMID:10539380. |
designed to provide information about patients with schizophrenia who switch from depot neuroleptics to the oral, atypical antipsychotic risperidone, this multicenter observational study enrolled patients who wished to stop the depot, had an unsatisfactory response, or experienced unacceptable side effects. |
1999-09-14 |
2023-08-12 |
Not clear |
| T I Prior, P S Chue, P Tibbo, G B Bake. Drug metabolism and atypical antipsychotics. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 9. issue 4. 1999-09-03. PMID:10422890. |
the introduction of the atypical antipsychotics clozapine, risperidone, olanzapine, quetiapine and sertindole for the treatment of schizophrenia has coincided with an increased awareness of the potential of drug-drug interactions, particularly involving the cytochrome p450 (cyp) enzymes. |
1999-09-03 |
2023-08-12 |
Not clear |
| A K Malla, R M Norman, V Kotteda, S Ziru. Switching from therapy with typical antipsychotic agents to risperidone: long-term impact on patient outcome. Clinical therapeutics. vol 21. issue 5. 1999-09-02. PMID:10397376. |
results of this study suggest that a switch to risperidone therapy because of the inefficacy of typical antipsychotic agents or patients' inability to tolerate them may lead to sustained and significant improvement in a substantial proportion of patients with schizophrenia. |
1999-09-02 |
2023-08-12 |
Not clear |
| H Y Lane, W H Chan. Clozapine versus risperidone in treatment-refractory schizophrenia: possible impact of dosing strategies. The Journal of clinical psychiatry. vol 60. issue 7. 1999-08-27. PMID:10453806. |
clozapine versus risperidone in treatment-refractory schizophrenia: possible impact of dosing strategies. |
1999-08-27 |
2023-08-12 |
Not clear |
| C M Kalinya. Schizophrenia treatment: the use of atypical drugs--risperdal, zyperexa, and clozaril. The international journal of psychiatric nursing research. vol 4. issue 2. 1999-08-26. PMID:10451301. |
schizophrenia treatment: the use of atypical drugs--risperdal, zyperexa, and clozaril. |
1999-08-26 |
2023-08-12 |
Not clear |
| H Y Meltze. Risperidone and clozapine for treatment-resistant schizophrenia. The American journal of psychiatry. vol 156. issue 7. 1999-07-30. PMID:10401484. |
risperidone and clozapine for treatment-resistant schizophrenia. |
1999-07-30 |
2023-08-12 |
Not clear |
| E Rubi. Risperidone and clozapine for treatment-resistant schizophrenia. The American journal of psychiatry. vol 156. issue 7. 1999-07-30. PMID:10401485. |
risperidone and clozapine for treatment-resistant schizophrenia. |
1999-07-30 |
2023-08-12 |
Not clear |
| E Dunayevich, A Chatterje. Risperidone and clozapine for treatment-resistant schizophrenia. The American journal of psychiatry. vol 156. issue 7. 1999-07-30. PMID:10401486. |
risperidone and clozapine for treatment-resistant schizophrenia. |
1999-07-30 |
2023-08-12 |
Not clear |
| D A Revick. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia. Schizophrenia research. vol 35 Suppl. 1999-07-21. PMID:10190231. |
the current pharmacoeconomic evidence suggests that clozapine is a cost-effective therapy for neuroleptic-refractory schizophrenia and that although olanzapine and risperidone therapy may be cost neutral, they improve outcome in patients treated for schizophrenia. |
1999-07-21 |
2023-08-12 |
Not clear |
| Y H Huang, S J Tsai, H J Huang, C B Si. The effect of acute administration of risperidone on local cerebral glucose utilization in the rat. European journal of pharmacology. vol 370. issue 3. 1999-07-16. PMID:10334500. |
risperidone (r 64 766, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-pyperidinyl]ethyl )-6,7,8,9-tetrahydro-2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one) has superior effects in treating negative symptoms of schizophrenia and causes less extrapyramidal side effects than traditional antipsychotics. |
1999-07-16 |
2023-08-12 |
rat |
| D A Wirshing, W C Wirshing, L Kysar, M A Berisford, D Goldstein, J Pashdag, J Mintz, S R Marde. Novel antipsychotics: comparison of weight gain liabilities. The Journal of clinical psychiatry. vol 60. issue 6. 1999-07-13. PMID:10401912. |
we performed a retrospective analysis of 122 clinical records of 92 male patients with dsm-iii-r schizophrenia to examine the relative weight gain liabilities of clozapine, risperidone, olanzapine, and sertindole compared with haloperidol. |
1999-07-13 |
2023-08-12 |
Not clear |
| S A Chong, H L Yap, B L Low, C H Choo, A O Chan, K E Wong, R Mahendran, K T Che. Clinical evaluation of risperidone in Asian patients with schizophrenia in Singapore. Singapore medical journal. vol 40. issue 1. 1999-06-29. PMID:10361485. |
clinical evaluation of risperidone in asian patients with schizophrenia in singapore. |
1999-06-29 |
2023-08-12 |
Not clear |
| S A Chong, H L Yap, B L Low, C H Choo, A O Chan, K E Wong, R Mahendran, K T Che. Clinical evaluation of risperidone in Asian patients with schizophrenia in Singapore. Singapore medical journal. vol 40. issue 1. 1999-06-29. PMID:10361485. |
to evaluate the short-term efficacy and safety of risperidone in a group of asian patients with schizophrenia in an 8-week open-label, prospective study. |
1999-06-29 |
2023-08-12 |
Not clear |